14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Jan 07, 2026
FGEN vs AKRO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Jan 07, 2026, Akero Therapeutics, Inc. (AKRO) captures the overall head-to-head institutional edge over FibroGen, Inc (FGEN) on higher Unified Composite conviction (60.0/100 BUY vs. 61.2/100 BUY) after splitting the core matrix 5–5 (led by Profitability & Quality), while FGEN wins 3–1 across the 6-pillar growth and valuation breakdown. FGEN trades at $9.71 (61.4x Forward P/E, -499.1% operating margin) versus AKRO at $54.65 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While FGEN currently prints a higher short-term Unified Composite Score (61.2/100 BUY vs. AKRO 60.0/100 BUY), AKRO captures the overall institutional head-to-head verdict (5–5 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -499.1% operating margin) and revenue trajectory (+0.0% vs. +774.8% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FGEN vs AKRO. Trailing 12-month operating profitability (FGEN -499.1% vs AKRO 0.0%) and valuation multiples (FGEN 61.4x vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ FGEN vs AKRO Key Questions & Quantitative Answers
As of Jan 07, 2026, Akero Therapeutics, Inc. (AKRO) captures the overall head-to-head institutional edge over FibroGen, Inc (FGEN) on higher Unified Composite conviction (60.0/100 BUY vs. 61.2/100 BUY) after splitting the core matrix 5–5 (led by Profitability & Quality), while FGEN wins 3–1 across the 6-pillar growth and valuation breakdown. FGEN trades at $9.71 (61.4x Forward P/E, -499.1% operating margin) versus AKRO at $54.65 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While FGEN currently prints a higher short-term Unified Composite Score (61.2/100 BUY vs. AKRO 60.0/100 BUY), AKRO captures the overall institutional head-to-head verdict (5–5 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -499.1% operating margin) and revenue trajectory (+0.0% vs. +774.8% YoY).
FGEN leads the Growth & Scale pillar: FGEN posts +774.8% YoY revenue growth and +53.6% YoY earnings growth on $8.3M TTM revenue (N/A gross margin, -499.1% operating margin), compared with AKRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, FGEN generates $8.3M in USD-normalized revenue versus N/A for AKRO. In operating R&D and SG&A reinvestment, FGEN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKRO.
FGEN screens cheaper on headline valuation multiples. FGEN trades at 61.4x Forward P/E, 61.4x Trailing P/E, N/M PEG, and 4.4x EV/Revenue (unreported EBITDA margin), whereas AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FGEN (-1015.8% ROE) versus AKRO (-34.5% ROE) capital efficiency.
In options market volatility and institutional positioning, FGEN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-20.79β · 102% Vol realized risk). By comparison, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Jan 07, 2026. For educational research only; not investment advice.